TNDM Tandem Diabetes Care
- 47.300
- +0.370+0.79%
- 47.670
- +0.370+0.78%
Tandem Diabetes Care News
Tandem Diabetes Care Recalls Version 2.7 Of Apple iOS T:Connect Mobile App Used With T:Slim X2 Insulin Pump With Control-IQ Technology
Tandem Diabetes Care Recalls Version 2.7 Of Apple iOS T:Connect Mobile App Used With T:Slim X2 Insulin Pump With Control-IQ Technology
Research Alert: CFRA Keeps Hold Opinion On Shares Of Tandem Diabetes Care, Inc.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lift our target price to $48 from $36
Tandem Diabetes Care Is Maintained at Overweight by Barclays
Tandem Diabetes Care Is Maintained at Overweight by Barclays
Tandem Diabetes Care Price Target Raised to $55.00/Share From $39.00 by Barclays
Tandem Diabetes Care Price Target Raised to $55.00/Share From $39.00 by Barclays
Barclays Maintains Overweight on Tandem Diabetes Care, Raises Price Target to $55
Barclays analyst Matt Miksic maintains Tandem Diabetes Care with a Overweight and raises the price target from $39 to $55.
Barclays Reaffirms Their Buy Rating on Tandem Diabetes Care (TNDM)
Earnings Update: Here's Why Analysts Just Lifted Their Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Price Target To US$43.57
Why Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Could Be Worth Watching
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), might not be a large cap stock, but it received a lot of attention from a substantial price increase on the NASDAQGM over the last few months. The recen
Tandem Diabetes Care Price Target Raised to $50.00/Share From $45.00 by Wells Fargo
Tandem Diabetes Care Price Target Raised to $50.00/Share From $45.00 by Wells Fargo
Tandem Diabetes Care Is Maintained at Overweight by Wells Fargo
Tandem Diabetes Care Is Maintained at Overweight by Wells Fargo
Nasdaq Surges 2%; Apple Posts Upbeat Results
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining 2% on Friday.The Dow traded up 1.16% to 38,670.87 while the NASDAQ rose 2% to 16,157.26. The S&P 500 also rose, gain
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q1 2024 Earnings Call Transcript
UBS Adjusts Price Target on Tandem Diabetes Care to $40 From $28, Maintains Neutral Rating
Tandem Diabetes Care (TNDM) has an average outperform rating and a price target range of $18 to $60, according to analysts polled by Capital IQ. Price: 45.19, Change: +8.63, Percent Change: +23.59
Tandem Diabetes Care Up Nearly 25%, on Pace for Largest Percent Increase Since February 2019 -- Data Talk
Tandem Diabetes Care, Inc. (TNDM) is currently at $45.69, up $9.13 or 24.97% --Would be highest close since Jan. 6, 2023, when it closed at $46.10 --On pace for largest percent increase since Feb. 2
Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Dow Jones index gaining over 400 points on Friday.Shares of Amgen Inc. (NASDAQ:AMGN) rose sharply during Friday's session after the company reported better-than-expec
AEON Biopharma, Allarity Therapeutics, ModivCare Among Healthcare Movers
Piper Sandler: Reiterates the Tandem Diabetes Care (TNDM.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $35.00 to $50.00.
Piper Sandler: Reiterates the Tandem Diabetes Care (TNDM.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $35.00 to $50.00.
Piper Sandler Reiterates Overweight on Tandem Diabetes Care, Raises Price Target to $50
Piper Sandler analyst Matt O'Brien reiterates Tandem Diabetes Care (NASDAQ:TNDM) with a Overweight and raises the price target from $35 to $50.
Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM) and Castle Biosciences (CSTL)
Tandem Diabetes Care (TNDM) Gets a Buy From Piper Sandler
Analysis
Price Target
No Data
